AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29282676 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan (Volibris tablet 2.5 mg)
Number of subjects: 702
Study 29282881 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with overweight/obesity (≥ 85th BMI-for-age percentile)
Number of subjects: 233
Study 29282881 — intervention group
Group type: EXPERIMENTAL
Intervention: Congruent trial mean accuracy and reaction time
Number of subjects: 233
Study 29282881 — intervention group
Group type: EXPERIMENTAL
Intervention: Incongruent trials
Number of subjects: 233
Study 29284010 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 10 mg/kg administered every 2 weeks for up to 2 years or until disease progression/unacceptable toxicity
Number of subjects: 23
Study 29284010 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 23
Study 29284181 — intervention group
Group type: EXPERIMENTAL
Intervention: T-Track assay
Number of subjects: 0
Study 29284202 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks
Number of subjects: 26
Study 29284435 — intervention group
Group type: EXPERIMENTAL
Intervention: Trivalent influenza vaccine (TIV)
Number of subjects: 0
Study 29284455 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined corneal wavefront-guided transepithelial photorefractive keratectomy (tPRK) and accelerated corneal collagen cross-linking (CXL) after intracorneal ring segment (ICRS) implantation
Number of subjects: 23
Study 29284455 — intervention group
Group type: EXPERIMENTAL
Intervention: ICRS implantation
Number of subjects: 23
Study 29284455 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined tPRK and CXL after ICRS implantation
Number of subjects: 23
Study 29284461 — intervention group
Group type: EXPERIMENTAL
Intervention: 405 nm light-emitting diode device
Number of subjects: 28
Study 29284461 — intervention group
Group type: COMPARATOR
Intervention: Commercial image-processing based plaque-imaging device
Number of subjects: 28
Study 29284510 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose, prophylactic naloxone infusion
Number of subjects: 96
Study 29284510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 29284521 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based resistance exercise group (HBRX)
Number of subjects: 40
Study 29284521 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group (CON)
Number of subjects: 40
Study 29284530 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan standard SBP control (SBP < 140 mmHg)
Number of subjects: 0
Study 29284530 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan strict SBP control (SBP < 130 mmHg)
Number of subjects: 0
Study 29284530 — intervention group
Group type: COMPARATOR
Intervention: Losartan standard SBP control
Number of subjects: 0
Study 29284530 — intervention group
Group type: COMPARATOR
Intervention: Losartan strict SBP control
Number of subjects: 0
Study 29284530 — intervention group
Group type: EXPERIMENTAL
Intervention: Fimasartan (after 24 weeks)
Number of subjects: 0
Study 29284530 — intervention group
Group type: COMPARATOR
Intervention: Losartan (after 24 weeks)
Number of subjects: 0
Study 29284596 — intervention group
Group type: EXPERIMENTAL
Intervention: High-throughput sequencing (HTS) of measurable residual disease (MRD)
Number of subjects: 0
Study 29284596 — intervention group
Group type: COMPARATOR
Intervention: Induction chemotherapy
Number of subjects: 0
Study 29284607 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss (WL)
Number of subjects: 95
Study 29284607 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Loss plus Exercise (WLEX)
Number of subjects: 95
Study 29284607 — intervention group
Group type: COMPARATOR
Intervention: No Treatment (Control)
Number of subjects: 95
Study 29285038 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel and Gemcitabine (Neoadjuvant Chemotherapy)
Number of subjects: 98
Study 29285668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/m² administered in second-(or later) setting, median of two cycles.
Number of subjects: 65
Study 29285668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/m²
Number of subjects: 65
Study 29288065 — intervention group
Group type: EXPERIMENTAL
Intervention: Euclidean length measurement for urinary incontinence severity
Number of subjects: 0
Study 29288159 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 0
Study 29288176 — intervention group
Group type: EXPERIMENTAL
Intervention: bDMARD treatment
Number of subjects: 1352
Study 29288176 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 1352
Study 29288176 — intervention group
Group type: EXPERIMENTAL
Intervention: Male gender
Number of subjects: 1352
Study 29288176 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index score
Number of subjects: 1352
Study 29288237 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomics-driven precision medicine
Number of subjects: 0
Study 29288237 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29288549 — intervention group
Group type: EXPERIMENTAL
Intervention: βAir device containing allogeneic human pancreatic islets
Number of subjects: 4
Study 29288911 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel monotherapy
Number of subjects: 60
Study 29288911 — intervention group
Group type: EXPERIMENTAL
Intervention: Perampanel secondary monotherapy
Number of subjects: 60
Study 29288911 — intervention group
Group type: COMPARATOR
Intervention: Perampanel adjunctive treatment
Number of subjects: 60
Study 29289501 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed suction drains
Number of subjects: 0
Study 29289501 — intervention group
Group type: COMPARATOR
Intervention: Negative pressure drains
Number of subjects: 0
Study 29289757 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandem autologous hematopoietic stem cell transplant (AHSCT)
Number of subjects: 0
Study 29289757 — intervention group
Group type: COMPARATOR
Intervention: Salvage therapy
Number of subjects: 0
Study 29289814 — intervention group
Group type: EXPERIMENTAL
Intervention: hrHPV testing of Evalyn self-collection device
Number of subjects: 310
Study 29289814 — intervention group
Group type: COMPARATOR
Intervention: Physician-specimen
Number of subjects: 310
Study 29289939 — intervention group
Group type: EXPERIMENTAL
Intervention: Low neighbourhood SES tertile
Number of subjects: 1645
Study 29289939 — intervention group
Group type: COMPARATOR
Intervention: High neighbourhood SES tertile
Number of subjects: 1645
Study 29290251 — intervention group
Group type: EXPERIMENTAL
Intervention: DLL3-high expression (positive in at least 50% of cancer cells)
Number of subjects: 63
Study 29290251 — intervention group
Group type: EXPERIMENTAL
Intervention: DLL3 expression status
Number of subjects: 63
Study 29290251 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 63
Study 29290515 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed airflow obstruction (FAO) defined as post-bronchodilator ratio of forced expiratory volume in 1 second to forced vital capacity ≤70%
Number of subjects: 186
Study 29290515 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed airflow obstruction (FAO)
Number of subjects: 186
Study 29290601 — intervention group
Group type: EXPERIMENTAL
Intervention: VICI VENOUS STENT
Number of subjects: 30
Study 29290809 — intervention group
Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Number of subjects: 25
Study 29292064 — intervention group
Group type: EXPERIMENTAL
Intervention: DREAMS 2G (drug-eluting absorbable metal scaffold)
Number of subjects: 123
Study 29292203 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone-Trial
Number of subjects: 2
Study 29292203 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxantel-Trial
Number of subjects: 2
Study 29292311 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Zero Exposure intervention (motivational interviews, feedback on child biomarker and home air quality, website, video, self-help materials)
Number of subjects: 26
Study 29292311 — intervention group
Group type: EXPERIMENTAL
Intervention: Project Zero Exposure intervention
Number of subjects: 26
Study 29292843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ontuxizumab at 12 mg/kg
Number of subjects: 27
Study 29292843 — intervention group
Group type: EXPERIMENTAL
Intervention: Ontuxizumab
Number of subjects: 27
Study 29293889 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg od
Number of subjects: 50
Study 29293893 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosmidomycin-piperaquine (30 mg/kg twice daily for fosmidomycin and 16 mg/kg once daily for piperaquine for 3 days)
Number of subjects: 100
Study 29293893 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosmidomycin-piperaquine
Number of subjects: 100
Study 29293895 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir plus Lamivudine
Number of subjects: 0
Study 29293895 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 29293942 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected participants
Number of subjects: 170
Study 29293942 — intervention group
Group type: COMPARATOR
Intervention: Uninfected control participants
Number of subjects: 170
Study 29294006 — intervention group
Group type: EXPERIMENTAL
Intervention: PDK4 expression in PBMCs and adipose tissue
Number of subjects: 10
Study 29294006 — intervention group
Group type: EXPERIMENTAL
Intervention: PDK4 expression in PBMCs
Number of subjects: 10
Study 29294006 — intervention group
Group type: EXPERIMENTAL
Intervention: FFAs
Number of subjects: 10
Study 29296107 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab with rapid oral immunotherapy (OIT)
Number of subjects: 34
Study 29296107 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term maintenance dosing of food allergens
Number of subjects: 34
Study 29296283 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who developed heart failure (HF) after STEMI
Number of subjects: 1459
Study 29296283 — intervention group
Group type: COMPARATOR
Intervention: Patients without heart failure (controls)
Number of subjects: 1459
Study 29296283 — intervention group
Group type: EXPERIMENTAL
Intervention: Crude incidence rate of HF after STEMI
Number of subjects: 1459
Study 29296283 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak creatine kinase MB (CK-MB) levels
Number of subjects: 1459
Study 29296283 — intervention group
Group type: EXPERIMENTAL
Intervention: Left anterior descending artery (LAD) culprit lesion
Number of subjects: 1459
Study 29296710 — intervention group
Group type: EXPERIMENTAL
Intervention: Epstein-Barr virus (EBV) DNA in cell-free blood at baseline
Number of subjects: 0
Study 29296710 — intervention group
Group type: EXPERIMENTAL
Intervention: Epstein-Barr virus (EBV) DNA in cell-free blood 8 days after initiation of therapy
Number of subjects: 0
Study 29296707 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttransplant cyclophosphamide (PT-Cy) at 0 mg/kg in cohort 1
Number of subjects: 23
Study 29296707 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttransplant cyclophosphamide (PT-Cy) at 50 mg/kg in cohort 2
Number of subjects: 23
Study 29296707 — intervention group
Group type: EXPERIMENTAL
Intervention: Posttransplant cyclophosphamide (PT-Cy) at 100 mg/kg in cohort 3
Number of subjects: 23
Study 29296707 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 23
Study 29296707 — intervention group
Group type: EXPERIMENTAL
Intervention: Graft-versus-host disease (GVHD)
Number of subjects: 23
Study 29296751 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06747143
Number of subjects: 0
Study 29296758 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) 1.2 mg/m²
Number of subjects: 24
Study 29296758 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) 1.6 mg/m²
Number of subjects: 24
Study 29296758 — intervention group
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin (InO) 1.8 mg/m²
Number of subjects: 24
Study 29296761 — intervention group
Group type: EXPERIMENTAL
Intervention: CD34+ hematopoietic stem cell transplantation from alternative donors
Number of subjects: 10
Study 29296798 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat with lenalidomide and dexamethasone (FRD)
Number of subjects: 27
Study 29296798 — intervention group
Group type: EXPERIMENTAL
Intervention: Panobinostat with lenalidomide and dexamethasone (FRD) in lenalidomide-refractory patients
Number of subjects: 27
Study 29296805 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib + Rituximab (IR; 375 mg/m2)
Number of subjects: 79
Study 29296805 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib + Bendamustine
Number of subjects: 79
Study 29296805 — intervention group
Group type: EXPERIMENTAL
Intervention: Idelalisib + Rituximab + Bendamustine
Number of subjects: 79
Study 29296838 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib (200 mg/day, 400 mg/day, 600 mg/day) for up to 12 cycles of 28 days each
Number of subjects: 17
Study 29296838 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonidegib
Number of subjects: 17
Study 29296867 — intervention group
Group type: EXPERIMENTAL
Intervention: third-party virus-specific T cells (VSTs)
Number of subjects: 30
Study 29296873 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib maintenance therapy after tandem autologous/allogeneic hematopoietic cell transplantation
Number of subjects: 0
Study 29296873 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose conditioning regimen with melphalan 200 mg/m2 for autologous hematopoietic cell transplantation
Number of subjects: 0
Study 29296893 — intervention group
Group type: EXPERIMENTAL
Intervention: Early progression of disease (POD)
Number of subjects: 829
Study 29296893 — intervention group
Group type: EXPERIMENTAL
Intervention: Late progression of disease (POD)
Number of subjects: 829
Study 29296893 — intervention group
Group type: EXPERIMENTAL
Intervention: No progression of disease (POD)
Number of subjects: 829
Study 29296893 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable-risk cytogenetics (del[11q]/del[17p])
Number of subjects: 829
Study 29297178 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D movie using oculus glasses and smartphone
Number of subjects: 100
Study 29297386 — intervention group
Group type: EXPERIMENTAL
Intervention: Informal health providers (traditional birth attendants, traditional healers, village doctors)
Number of subjects: 32
Study 29297386 — intervention group
Group type: COMPARATOR
Intervention: Government facility-based care
Number of subjects: 32
Study 29297386 — intervention group
Group type: EXPERIMENTAL
Intervention: Community level interventions and health worker mobilization
Number of subjects: 32
Study 29297386 — intervention group
Group type: EXPERIMENTAL
Intervention: Training for informal providers
Number of subjects: 32
Study 29297412 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal deaths
Number of subjects: 40
Study 29297412 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal illness
Number of subjects: 40
Study 29297412 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived postpartum hemorrhage (PPH)
Number of subjects: 40
Study 29297412 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal deaths
Number of subjects: 40
Study 29297412 — intervention group
Group type: EXPERIMENTAL
Intervention: Health services
Number of subjects: 40
Study 29297412 — intervention group
Group type: EXPERIMENTAL
Intervention: Spiritual care
Number of subjects: 40
Study 29297412 — intervention group
Group type: EXPERIMENTAL
Intervention: Interventions
Number of subjects: 40
Study 29297412 — intervention group
Group type: EXPERIMENTAL
Intervention: Perception of outcomes
Number of subjects: 40
Study 29298115 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based tracking and feedback (T&F) tool
Number of subjects: 10
Study 29298115 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 10
Study 29298525 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG-IUS)
Number of subjects: 512
Study 29298525 — intervention group
Group type: COMPARATOR
Intervention: Copper intrauterine device (Cu-IUD)
Number of subjects: 512
Study 29298669 — intervention group
Group type: EXPERIMENTAL
Intervention: Preferred prenatal counselling protocols
Number of subjects: 205
Study 29298669 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint counselling by neonatologist and obstetrician
Number of subjects: 205
Study 29298669 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of supportive materials
Number of subjects: 205
Study 29298669 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of national or local data on outcome statistics
Number of subjects: 205
Study 29298669 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision model
Number of subjects: 205
Study 29298749 — intervention group
Group type: EXPERIMENTAL
Intervention: Active participation in SmartCare service (transmitting data 3+ times/week or health consultations 5+ times in 24 weeks)
Number of subjects: 405
Study 29298749 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive participation in SmartCare service (did not meet active criteria)
Number of subjects: 405
Study 29298749 — intervention group
Group type: COMPARATOR
Intervention: Control group (did not use SmartCare service)
Number of subjects: 405
Study 29298749 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 405
Study 29298798 — intervention group
Group type: EXPERIMENTAL
Intervention: M7824 (MSB0011359C)
Number of subjects: 0
Study 29298867 — intervention group
Group type: EXPERIMENTAL
Intervention: dezamizumab (fully humanized monoclonal IgG1 anti-SAP antibody)
Number of subjects: 23
Study 29298867 — intervention group
Group type: EXPERIMENTAL
Intervention: miridesap (small-molecule drug)
Number of subjects: 23
Study 29299030 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan
Number of subjects: 171
Study 29299030 — intervention group
Group type: EXPERIMENTAL
Intervention: Discontinuation of warfarin in low-risk patients with sustained sinus rhythm
Number of subjects: 171
Study 29299030 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 29299030 — intervention group
Group type: COMPARATOR
Intervention: Reference group (subjects without AF)
Number of subjects: 171
Study 29299303 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-based hand rub (ABHR) and training for hand hygiene (HH) practice during the intervention phase.
Number of subjects: 3335
Study 29299303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention phase with ABHR and training for HH practice.
Number of subjects: 3335
Study 29299336 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance cardiography (ICG) derived systolic time ratio (STR)
Number of subjects: 0
Study 29299336 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance cardiography (ICG) derived pre-ejection period (PEP)
Number of subjects: 0
Study 29299336 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance cardiography (ICG) derived left ventricle ejection time (LVET)
Number of subjects: 0
Study 29299336 — intervention group
Group type: EXPERIMENTAL
Intervention: Impedance cardiography (ICG) derived D wave
Number of subjects: 0
Study 29299340 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXEQ4W)
Number of subjects: 0
Study 29299340 — intervention group
Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (IXEQ2W)
Number of subjects: 0
Study 29299340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 29299402 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-valent PCV (10vPCV)
Number of subjects: 262
Study 29299402 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent PCV (13vPCV)
Number of subjects: 262
Study 29299402 — intervention group
Group type: EXPERIMENTAL
Intervention: PPV
Number of subjects: 262
Study 29299402 — intervention group
Group type: COMPARATOR
Intervention: No PPV
Number of subjects: 262
Study 29299952 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer concentrations at early follow-up
Number of subjects: 421
Study 29299952 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin peak at early follow-up
Number of subjects: 421
Study 29299952 — intervention group
Group type: EXPERIMENTAL
Intervention: Endogenous thrombin potential (ETP) at early follow-up
Number of subjects: 421
Study 29299962 — intervention group
Group type: EXPERIMENTAL
Intervention: ROTEM®
Number of subjects: 50
Study 29300435 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower mean MNA scores (Mini Nutritional Assessment)
Number of subjects: 244
Study 29300435 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary heart disease, systolic and diastolic blood pressure in a sitting position, lower mean MNA scores
Number of subjects: 244
Study 29300435 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthostatic hypotension (OH) prevalence
Number of subjects: 244
Study 29300435 — intervention group
Group type: COMPARATOR
Intervention: Number of drugs used or causative drug use
Number of subjects: 244
Study 29300902 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle AEA concentration
Number of subjects: 56
Study 29300902 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle 2-AG concentration
Number of subjects: 56
Study 29300902 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose OEA concentration
Number of subjects: 56
Study 29300902 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma OEA concentration
Number of subjects: 56
Study 29300960 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week intensive exercise intervention
Number of subjects: 26
Study 29300991 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-induced hypoglycemia
Number of subjects: 19
Study 29300991 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe iatrogenic hypoglycemia
Number of subjects: 19
Study 29300991 — intervention group
Group type: COMPARATOR
Intervention: Matched inpatient and outpatient controls
Number of subjects: 19
Study 29301463 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization-associated disability (HAD)
Number of subjects: 80
Study 29301463 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical restraints
Number of subjects: 80
Study 29301463 — intervention group
Group type: EXPERIMENTAL
Intervention: Indwelling catheters
Number of subjects: 80
Study 29301463 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive pressure ulcer measures
Number of subjects: 80
Study 29301463 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital stay duration
Number of subjects: 80